Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab.

Link:
Autor/in:
Erscheinungsjahr:
2012
Medientyp:
Text
Beschreibung:
  • We investigated in the first-line setting our previous finding that patients with chemorefractory KRAS G13D-mutated metastatic colorectal cancer (mCRC) benefit from cetuximab treatment.
  • We investigated in the first-line setting our previous finding that patients with chemorefractory KRAS G13D-mutated metastatic colorectal cancer (mCRC) benefit from cetuximab treatment.
Lizenz:
  • info:eu-repo/semantics/restrictedAccess
Quellsystem:
Forschungsinformationssystem des UKE
Interne Metadaten
Quelldatensatz
oai:pure.atira.dk:publications/6609a906-a585-480f-b2f2-8267276888fe